Sionna Q2 Loss Widens to $29.9M; Cash Runway into 2028, Key Data Readouts This Summer

summarizeSummary

Sionna reported a wider Q2 loss of $29.9M, guided cash runway into 2028, and confirmed two key clinical data readouts this summer. A $250M ATM program is in place but unused.

check_boxKey Events · Earnings and Guidance · SION

• Q2 Net Loss Widens

  Net loss of $29.9M vs $18.1M in Q2 2025, driven by a $6.5M increase in R&D expenses to $21.9M as clinical programs advance.

• Cash Runway into 2028

  Cash, equivalents, and marketable securities totaled $268.3M at June 30, 2026. Management expects this to fund operations into 2028.

• Key Data Readouts This Summer

  Topline data from the Phase 2a trial of SION-719 (add-on to standard of care) and the Phase 1 dual combination trial of SION-451 are expected in summer 2026.

• $250M ATM Program Established

  In March 2026, the company entered into a sales agreement for an at-the-market equity program of up to $250M. No shares have been sold as of June 30, 2026.

auto_awesomeAnalysis · SION · Life Sciences

Sionna's Q2 2026 net loss grew to $29.9 million from $18.1 million a year ago, driven by higher R&D spending as its NBD1 stabilizer programs advance. The company ended the quarter with $268.3 million in cash and securities, which management says funds operations into 2028. Two critical clinical readouts are expected this summer: Phase 2a data for SION-719 as an add-on to standard of care, and Phase 1 data for SION-451 in dual combinations. The company also disclosed a $250 million at-the-market equity program established in March, though no shares have been sold. The combination of a widening loss, a large but untapped ATM overhang, and near-term binary catalysts makes this a pivotal quarter for the stock.